Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study Sune F Nielsen, PhD, Prof Børge G Nordestgaard, MD The Lancet Diabetes & Endocrinology Volume 2, Issue 11, Pages 894-900 (November 2014) DOI: 10.1016/S2213-8587(14)70173-1 Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile *Fibrates, bile acid sequestrants, nicotin acid and derivatives, and others (including ezetimibe). † Irregular use ascertained in the period before diabetes diagnosis; regular use defined as two prescriptions for statins, one obtained within 2 years before diabetes diagnosis and one within 6 months before diabetes diagnosis. The Lancet Diabetes & Endocrinology 2014 2, 894-900DOI: (10.1016/S2213-8587(14)70173-1) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 2 Cumulative incidence of microvascular diseases and gangrene according to statin use Cumulative incidence among individuals with incident diabetes. The Lancet Diabetes & Endocrinology 2014 2, 894-900DOI: (10.1016/S2213-8587(14)70173-1) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 3 Risk of microvascular diseases and gangrene, according to statin use Risk in (A) the total population with diabetes, (B) after adjustment for the competing risk of death, and (C) after matching for propensity score. The Lancet Diabetes & Endocrinology 2014 2, 894-900DOI: (10.1016/S2213-8587(14)70173-1) Copyright © 2014 Elsevier Ltd Terms and Conditions